JP2003521914A - トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター - Google Patents

トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター

Info

Publication number
JP2003521914A
JP2003521914A JP2001557910A JP2001557910A JP2003521914A JP 2003521914 A JP2003521914 A JP 2003521914A JP 2001557910 A JP2001557910 A JP 2001557910A JP 2001557910 A JP2001557910 A JP 2001557910A JP 2003521914 A JP2003521914 A JP 2003521914A
Authority
JP
Japan
Prior art keywords
inhibitor
human
milk
mammal
human mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001557910A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003521914A5 (cg-RX-API-DMAC7.html
Inventor
ヨハネス ヘンリクス ノイエンス,
フェーン, ヘンリクス アントニウス ファン
フランク エール. ピーピル,
ヨリス ヤン ヒュース,
Original Assignee
ファーミング インテレクチュアル プロパティー ベー.フェー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーミング インテレクチュアル プロパティー ベー.フェー. filed Critical ファーミング インテレクチュアル プロパティー ベー.フェー.
Publication of JP2003521914A publication Critical patent/JP2003521914A/ja
Publication of JP2003521914A5 publication Critical patent/JP2003521914A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/107—Rabbit
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C2230/00—Aspects relating to animal feed or genotype
    • A23C2230/05—Milk or milk products from transgenic animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
JP2001557910A 2000-01-31 2001-01-31 トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター Withdrawn JP2003521914A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US17931000P 2000-01-31 2000-01-31
EP00200320.0 2000-01-31
US60/179,310 2000-01-31
EP00200320 2000-01-31
US18758000P 2000-03-07 2000-03-07
US60/187,580 2000-03-07
EP00200810.0 2000-03-07
EP00200810 2000-03-07
PCT/NL2001/000068 WO2001057079A2 (en) 2000-01-31 2001-01-31 C1 inhibitor produced in the milk of transgenic mammals

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011270236A Division JP2012050465A (ja) 2000-01-31 2011-12-09 トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター

Publications (2)

Publication Number Publication Date
JP2003521914A true JP2003521914A (ja) 2003-07-22
JP2003521914A5 JP2003521914A5 (cg-RX-API-DMAC7.html) 2008-02-28

Family

ID=56290105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001557910A Withdrawn JP2003521914A (ja) 2000-01-31 2001-01-31 トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター

Country Status (9)

Country Link
EP (1) EP1252184B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003521914A (cg-RX-API-DMAC7.html)
AT (1) ATE382635T1 (cg-RX-API-DMAC7.html)
CA (1) CA2398707C (cg-RX-API-DMAC7.html)
DE (2) DE60132169T2 (cg-RX-API-DMAC7.html)
DK (1) DK1252184T3 (cg-RX-API-DMAC7.html)
ES (1) ES2299473T3 (cg-RX-API-DMAC7.html)
PT (1) PT1252184E (cg-RX-API-DMAC7.html)
WO (1) WO2001057079A2 (cg-RX-API-DMAC7.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009520815A (ja) * 2005-12-21 2009-05-28 ファーミング インテレクチュアル プロパティ ビー.ブイ. 虚血再灌流障害を予防するためのc1インヒビターの使用
JP2011526495A (ja) * 2008-06-30 2011-10-13 チョ−エー・ファーム・カンパニー・リミテッド 豚のαS1カゼイン遺伝子、そのプロモーター、及びその用途
JP2012050465A (ja) * 2000-01-31 2012-03-15 Pharming Intellectual Pty Bv トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター
JP2016511394A (ja) * 2013-01-20 2016-04-14 ダイアックス コーポレーション pKal関連疾病の評価、アッセイおよび治療
JP2021515757A (ja) * 2018-02-28 2021-06-24 ファーミング・インテレクチュアル・プロパティー・ビー.ブイ. 子癇前症の治療及び予防
US11754570B2 (en) 2019-04-16 2023-09-12 Takeda Pharmaceutical Company Limited Methods for quantitation of functional C1 esterase inhibitor (FC1-INH)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112617A1 (de) * 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
AU2003301332B2 (en) * 2002-10-17 2008-06-12 Pharming Intellectual Property B.V. Protein modification
EP1947116B1 (en) 2003-02-10 2017-06-21 2-BBB Medicines B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
US7544853B2 (en) * 2003-05-16 2009-06-09 Pharming Intellectual Property B.V. C1 inhibitor with short half-life transient treatment
FR2901796A1 (fr) * 2006-05-31 2007-12-07 Lab Francais Du Fractionnement Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
WO2010087702A1 (en) 2009-01-30 2010-08-05 Stichting Katholieke Universiteit TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
WO2011034421A1 (en) 2009-09-16 2011-03-24 Stichting Het Nederlands Kanker Instituut Fra-1 target genes as drug targets for treating cancer
EP2305717A1 (en) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Inhibiting TNIK for treating colon cancer
EP2354245A1 (en) 2010-02-04 2011-08-10 Stichting Top Institute Food and Nutrition MBL2 as a marker of hepatic PPAR- activity
EP2354244A1 (en) 2010-02-04 2011-08-10 Stichting Top Institute Food and Nutrition MBL2 as a marker of liver-specific insulin resistance
WO2012026820A2 (en) 2010-08-27 2012-03-01 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
EP2465928A1 (en) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Treatment of Th17-mediated diseases
EP2866826B1 (en) 2012-06-27 2025-08-06 Meiragtx UK II Limited Combination for treating an inflammatory disorder
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
ES2912396T3 (es) 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
ME02865B (me) 2013-03-15 2018-04-20 Shire Viropharma Inc C1-inh kompozicije za upotrebu u prevenciji i liječenju naslednog angioedema (hae)
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
EP4212175A1 (en) 2015-04-06 2023-07-19 Bioverativ USA Inc. Humanized anti-c1s antibodies and methods of use thereof
CN108463243B (zh) * 2015-11-19 2022-06-14 夏尔人类遗传性治疗公司 重组人c1酯酶抑制剂及其用途
IL326479A (en) 2016-10-12 2026-04-01 Bioverativ Usa Inc Anti-c1s antibodies and methods of use thereof
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
JP2024525084A (ja) 2021-07-09 2024-07-09 ファーミング・インテレクチュアル・プロパティー・ビー.ブイ. C1エステラーゼ阻害剤によるウイルス感染関連症状の治療
MA71249A (fr) 2022-06-24 2025-04-30 Bioverativ Usa Inc. Méthodes de traitement de maladies médiées par complément

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10504715A (ja) * 1994-07-27 1998-05-12 ファーミング ビー.ブイ. トランスジェニック哺乳動物の乳汁におけるコラーゲンの産生
WO1999051724A1 (en) * 1998-04-07 1999-10-14 Pharming Intellectual Property B.V. PURIFICATION OF HUMAN ACID α-GLUCOSIDASE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601034B1 (fr) * 1986-07-03 1989-11-17 Pasteur Institut Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese
WO1991006650A1 (en) * 1989-10-27 1991-05-16 Cetus Corporation C1 inhibitor muteins and uses thereof
WO1992022320A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE4227762A1 (de) * 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10504715A (ja) * 1994-07-27 1998-05-12 ファーミング ビー.ブイ. トランスジェニック哺乳動物の乳汁におけるコラーゲンの産生
WO1999051724A1 (en) * 1998-04-07 1999-10-14 Pharming Intellectual Property B.V. PURIFICATION OF HUMAN ACID α-GLUCOSIDASE

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6009021425; J. Mammary Gland Biol. Neoplasia 3(3)(1998), p.337-350 *
JPN6010067861; Lab. Invest. 65(4), p.381-388 *
JPN6010067863; J. Biol. Chem. 253(24)(1988), p.11776-11779 *
JPN6012012290; 'Journal of Clinical Investigation' 1989, Vol.84, p.443-450

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012050465A (ja) * 2000-01-31 2012-03-15 Pharming Intellectual Pty Bv トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター
JP2009520815A (ja) * 2005-12-21 2009-05-28 ファーミング インテレクチュアル プロパティ ビー.ブイ. 虚血再灌流障害を予防するためのc1インヒビターの使用
JP2011526495A (ja) * 2008-06-30 2011-10-13 チョ−エー・ファーム・カンパニー・リミテッド 豚のαS1カゼイン遺伝子、そのプロモーター、及びその用途
US9738694B2 (en) 2008-06-30 2017-08-22 Cho-A Pharm. Co., Ltd. Gene of porcine alpha-s1 casein, a promoter of the same and use thereof
JP2016511394A (ja) * 2013-01-20 2016-04-14 ダイアックス コーポレーション pKal関連疾病の評価、アッセイおよび治療
US10690670B2 (en) 2013-01-20 2020-06-23 Dyax Corp. Assays for determining levels of plasma protease C1 inhibitor
US11892450B2 (en) 2013-01-20 2024-02-06 Takeda Pharmaceutical Company Limited Evaluation, assays and treatment of pKal-mediated disorders
JP2021515757A (ja) * 2018-02-28 2021-06-24 ファーミング・インテレクチュアル・プロパティー・ビー.ブイ. 子癇前症の治療及び予防
US11754570B2 (en) 2019-04-16 2023-09-12 Takeda Pharmaceutical Company Limited Methods for quantitation of functional C1 esterase inhibitor (FC1-INH)

Also Published As

Publication number Publication date
DE60132169T2 (de) 2008-12-11
DK1252184T3 (da) 2008-02-04
CA2398707A1 (en) 2001-08-09
WO2001057079A3 (en) 2002-08-15
PT1252184E (pt) 2008-04-15
DE122011000002I1 (de) 2011-05-05
ES2299473T3 (es) 2008-06-01
EP1252184A2 (en) 2002-10-30
DE60132169D1 (de) 2008-02-14
ATE382635T1 (de) 2008-01-15
WO2001057079A2 (en) 2001-08-09
CA2398707C (en) 2010-10-26
EP1252184B1 (en) 2008-01-02

Similar Documents

Publication Publication Date Title
EP1252184B1 (en) Human c1 inhibitor produced in the milk of transgenic mammals
JP2014121337A (ja) トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター
CA2093659C (en) Dna sequence encoding bovine .alpha.-lactalbumin and methods of use
JPH10506013A (ja) ヒトの凝固第viii因子及びフォンビルブラント因子を発現するトランスジェニック動物
US20090239797A1 (en) Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
US6545198B1 (en) Transgenically produced prolactin
US7435869B2 (en) Transgenic nonhuman mammals producing fibrinogen in milk and methods of producing fibrin
US20130131317A1 (en) Expression of secreted human alpha-fetoprotein in transgenic animals
US7723563B2 (en) Transgenic proteins from multi-gene systems, methods, compositions, uses and the like relating thereto
JPH08511688A (ja) Ec−sodの形質転換生産
AU784724B2 (en) C1 inhibitor produced in the milk of transgenic mammals
AU2006203549B2 (en) C1 inhibitor produced in the milk of transgenic mammals
US20040117862A1 (en) Production of high levels of transgenic factor VII with engineered stability and its therapeutic uses
US20160361394A1 (en) Treatment of hereditary angioedema with c1 inhibitor
Brem et al. Transgenesis in rabbits
AU2002254193A1 (en) Production of high levels of transgenic factor VIII with engineered stability, and its therapeutic uses
JPH11239430A (ja) トランスジェニック哺乳動物
HK1121342A (en) Expression of secreted human alpha-fetoprotein in transgenic animals

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111209

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120124

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120309

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20140423